Dyne Therapeutics, Inc. DYN
Institutional shares held
92.1 Million
130K
calls
209K
puts
Total value of holdings
$2.65B
$3.73M
calls
$6.02M
puts
Market Cap
$1.43B
51,765,400
Shares Out.
Institutional ownership
177.9%
# of Institutions
177
We take great care to ensure that the data presented and summarized in this overview for Dyne Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DYN
View all-
Atlas Venture Life Science Advisors, LLC8.02MShares$222 Million28.49% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$217 Million31.49% of portfolio
-
Black Rock Inc. New York, NY5.39MShares$149 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.56MShares$126 Million4.27% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.25MShares$118 Million0.02% of portfolio
-
State Street Corp Boston, MA4.19MShares$116 Million0.01% of portfolio
-
Mpm Asset Management LLC Cambridge, MA3.45MShares$95.5 Million39.97% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.44MShares$95.2 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.09MShares$85.6 Million1.41% of portfolio
-
Janus Henderson Group PLC London, X02.68MShares$74.1 Million0.04% of portfolio
Latest Institutional Activity in DYN
Top Purchases
Top Sells
About DYN
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Insider Transactions at DYN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
2,588
-1.09%
|
$72,464
$28.4 P/Share
|
|
May 16
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,738
-0.88%
|
$76,664
$28.4 P/Share
|
|
May 16
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,381
-0.79%
|
$66,668
$28.4 P/Share
|
|
May 16
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,705
-0.89%
|
$75,740
$28.4 P/Share
|
|
May 16
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,774
-1.0%
|
$77,672
$28.4 P/Share
|
|
Mar 12
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,030
-0.68%
|
$25,750
$25.58 P/Share
|
|
Mar 11
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,292
-1.44%
|
$57,300
$25.7 P/Share
|
|
Mar 11
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
19,601
-6.23%
|
$490,025
$25.59 P/Share
|
|
Mar 11
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,825
+10.08%
|
$89,125
$5.54 P/Share
|
|
Mar 11
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
66,387
-2.84%
|
$1,659,675
$25.89 P/Share
|
|
Mar 11
2024
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.64%
|
$250,000
$5.54 P/Share
|
|
Mar 11
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
2,672
-1.1%
|
$66,800
$25.35 P/Share
|
|
Mar 11
2024
|
Wildon Farwell Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,585
-1.03%
|
$39,625
$25.7 P/Share
|
|
Mar 11
2024
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,081
-1.35%
|
$52,025
$25.7 P/Share
|
|
Mar 08
2024
|
Susanna Gatti High Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
27,199
-7.31%
|
$734,373
$27.04 P/Share
|
|
Mar 08
2024
|
Jonathan Mc Neill Chief Business Officer |
SELL
Open market or private sale
|
Direct |
90,000
-14.43%
|
$2,340,000
$26.5 P/Share
|
|
Mar 08
2024
|
Jonathan Mc Neill Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+14.56%
|
$450,000
$5.54 P/Share
|
|
Mar 08
2024
|
Joshua T Brumm CEO & President |
SELL
Open market or private sale
|
Direct |
363,343
-14.86%
|
$9,446,918
$26.47 P/Share
|
|
Mar 08
2024
|
Joshua T Brumm CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
363,343
+18.22%
|
$1,816,715
$5.54 P/Share
|
|
Mar 08
2024
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
86,252
-15.37%
|
$2,242,552
$26.45 P/Share
|
Last 12 Months Summary
Buy / Acquisition
4M
Shares
From
11
Insiders
| Grant, award, or other acquisition | 816K shares |
|---|---|
| Exercise of conversion of derivative security | 1.47M shares |
| Open market or private purchase | 1.71M shares |
Sell / Disposition
5.51M
Shares
From
10
Insiders
| Open market or private sale | 5.47M shares |
|---|---|
| Bona fide gift | 43.3K shares |